NCT02457273 2019-04-03
Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients
National Health Research Institutes, Taiwan
Phase 2 Completed
National Health Research Institutes, Taiwan
Taiwan Liposome Company